Cargando…
Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary /
To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resist...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores principales: | , , , |
| Autores Corporativos: | , |
| Formato: | Electrónico Congresos, conferencias eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press,
[2013]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn823904672 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 130905s2013 dcua obt 100 0 eng | ||
| 040 | |a NLM |b eng |e rda |e pn |c NLM |d COO |d MMU |d UCNAP |d CUS |d E7B |d N$T |d YDXCP |d EBLCP |d DEBSZ |d OCLCO |d D6H |d VT2 |d OCLCQ |d COCUF |d OCLCO |d AGLDB |d OCLCA |d NLM |d ORU |d OCLCO |d MERUC |d OCLCA |d ZCU |d OCLCA |d U3W |d OCLCA |d OCLCF |d STF |d VTS |d EZ9 |d ICG |d OCLCQ |d OCLCO |d OCLCA |d LVT |d OCLCA |d TKN |d DKC |d AU@ |d OCLCQ |d K6U |d OCLCO |d UKAHL |d OCLCO |d OCLCA |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 101616608 |2 DNLM | |
| 019 | |a 880439901 |a 923290368 |a 971092568 | ||
| 020 | |a 9780309265980 |q (ebook) | ||
| 020 | |a 0309265983 |q (ebook) | ||
| 020 | |a 9780309265966 | ||
| 020 | |a 0309265967 | ||
| 020 | |z 9780309265959 |q (paperback) | ||
| 020 | |z 0309265959 |q (paperback) | ||
| 029 | 0 | |a NLM |b 101616608 | |
| 029 | 1 | |a DEBBG |b BV042793432 | |
| 029 | 1 | |a DEBBG |b BV044185137 | |
| 029 | 1 | |a DEBSZ |b 42458560X | |
| 029 | 1 | |a DEBSZ |b 452581605 | |
| 035 | |a (OCoLC)823904672 |z (OCoLC)880439901 |z (OCoLC)923290368 |z (OCoLC)971092568 | ||
| 042 | |a pcc | ||
| 050 | 4 | |a RC311.1 |b .W67 2012 | |
| 060 | 0 | 0 | |a WF 360 |
| 072 | 7 | |a POL |x 027000 |2 bisacsh | |
| 072 | 7 | |a POL |x 019000 |2 bisacsh | |
| 082 | 0 | 4 | |a 362.19699/5 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Nicholson, Anna, |e author. | |
| 245 | 1 | 0 | |a Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : |b workshop summary / |c Anna Nicholson, Rebecca A. English, Rita S. Guenther, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| 264 | 1 | |a Washington, D.C. : |b National Academies Press, |c [2013] | |
| 300 | |a 1 online resource (xvii, 152 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 500 | |a Title from PDF title page. | ||
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)--a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)--face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high-quality medicines to more of the people who need them. | |
| 536 | |a This activity was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and HHSF223001003T), Abbott Pharmaceuticals, American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly and Company, Eli Lilly & Co. Foundation, FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Janssen Research & Development, LLC, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc. | ||
| 588 | 0 | |a Version viewed: Oct. 26, 2013. | |
| 505 | 0 | |a Introduction -- Logistics, supply, and demand -- Financing of MD TB SLDs -- Innovative suggestions and potential solutions. | |
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Multidrug-resistant tuberculosis |x Prevention |v Congresses. | |
| 650 | 0 | |a Business logistics |v Congresses. | |
| 650 | 0 | |a International cooperation |v Congresses. | |
| 650 | 1 | 2 | |a Tuberculosis, Multidrug-Resistant |x drug therapy |
| 650 | 2 | 2 | |a Extensively Drug-Resistant Tuberculosis |x drug therapy |
| 650 | 2 | 2 | |a Internationality |
| 650 | 6 | |a Logistique (Organisation) |v Congrès. | |
| 650 | 6 | |a Coopération internationale |v Congrès. | |
| 650 | 7 | |a POLITICAL SCIENCE |x Public Policy |x Social Security. |2 bisacsh | |
| 650 | 7 | |a POLITICAL SCIENCE |x Public Policy |x Social Services & Welfare. |2 bisacsh | |
| 650 | 7 | |a Business logistics |2 fast | |
| 650 | 7 | |a International cooperation |2 fast | |
| 655 | 2 | |a Congress | |
| 655 | 7 | |a proceedings (reports) |2 aat | |
| 655 | 7 | |a Conference papers and proceedings |2 fast | |
| 655 | 7 | |a Conference papers and proceedings. |2 lcgft | |
| 655 | 7 | |a Actes de congrès. |2 rvmgf | |
| 700 | 1 | |a English, Rebecca A., |e author. | |
| 700 | 1 | |a Guenther, Rita S., |e author. | |
| 700 | 1 | |a Claiborne, Anne B., |e author. | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Forum on Drug Discovery, Development, and Translation, |e sponsoring body. | |
| 711 | 2 | |a Workshop on Global Drug Supply Chain for Secondline Anti-tuberculosis Drugs |d (2012 : |c Washington, D.C.) | |
| 758 | |i has work: |a Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis (Text) |1 https://id.oclc.org/worldcat/entity/E39PCH8XMKK83K6GbKjDYjHVFq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB. 2012 Washington, D.C. |t Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis. |d Washington, D.C. : National Academies Press, ©2013 |z 0309265959 |w (DLC) 2013427394 |w (OCoLC)828139251 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3379261 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36561312 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36617669 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL3379261 | ||
| 938 | |a ebrary |b EBRY |n ebr10863916 | ||
| 938 | |a EBSCOhost |b EBSC |n 867734 | ||
| 938 | |a YBP Library Services |b YANK |n 11864740 | ||
| 994 | |a 92 |b IZTAP | ||